Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-020021
Filing Date
2025-02-04
Accepted
2025-02-04 16:06:47
Documents
7
Effectiveness Date
2025-02-04

Document Format Files

Seq Description Document Type Size
1 S-8 d852234ds8.htm S-8 32423
2 EX-5.1 d852234dex51.htm EX-5.1 5601
3 EX-23.1 d852234dex231.htm EX-23.1 2224
4 EX-99.2 d852234dex992.htm EX-99.2 4337
5 EX-99.3 d852234dex993.htm EX-99.3 5013
6 EX-FILING FEES d852234dexfilingfees.htm EX-FILING FEES 26390
7 GRAPHIC g852234g0204031857846.jpg GRAPHIC 2629
  Complete submission text file 0001193125-25-020021.txt   80846
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-284687 | Film No.: 25588154
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)